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ABSTRACT
Objectives: The aim of the publication was to present the interdisciplinary guidelines of the Urogynecology Section of the 
Polish Society of Gynecologists and Obstetricians (PSGO) for the treatment of overactive bladder (OAB) syndrome based 
on the available literature, expert knowledge, and everyday practice. 
Material and methods: A review of the literature, including current recommendations for the treatment of overactive 
bladder syndrome, urinary incontinence, urgency and mixed urinary incontinence, as well as the earlier recommendations 
of the PSGO Urogynecology Section, was conducted. 
Results: Management of the patients with OAB is presented. Four lines of therapy were identified: 1) educating the patient, 
behavioral therapy with pelvic floor muscle training, 2) pharmacotherapy, 3) botulinum toxin injection and tibial nerve 
stimulation; and sacral nerve stimulation even though so far it has been used only in selected populations, 4) surgical in-
tervention. The literature reports which provided supporting evidence and presented various aspects of the therapy were 
discussed. OAB pharmacotherapy-related issues which are vital in everyday clinical practice were presented. 
Conclusions: A systematic review of the available guidelines and an analysis of OAB (including urgency urinary inconti-
nence) management were conducted. The Polish Society of Gynecologists and Obstetricians issued the guidelines for the 
therapeutic management of OAB patients.  The need for an individualized approach was emphasized.
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INTRODUCTION 
The mission of the Urogynecology Section of the Pol-
ish Society of Gynecologists and Obstetricians (PSGO) is to 
promote the development of urogynecology in Poland, sup-
port education, and set evidence-based standards for the 
management of urogynecologic diseases. The Urogynecol-
ogy Section issues certificates and awards credit points. The 
present update of the Guidelines concerns the treatment of 
the overactive bladder (OAB) syndrome.
Various fields of medicine benefit from guidelines and 
recommendations for the management of numerous dis-
eases issued by expert groups and associations. The aim of 
these guidelines is to set evidence-based standards and 
to present the current management of different diseases 
and conditions, in accordance with the global trends. Their 
content is based on the analysis of the available literature, 
having taken into consideration the specificity and resources 
of a given country.    
The guidelines present the current management of the 
disease, which may be modified and altered in justifiable 
cases and after a detailed analysis of the clinical situation, 
which in turn might lead to future updates of the recom-
mendations. Both, the patient and the treatment always 
require an individualized approach. Also, it is possible to 
apply other than recommended, and in some cases even 
off-label, therapies.
The available literature on the overactive bladder syn-
drome mostly relates to patients with mixed urinary incon-
tinence or with urinary incontinence (UI). The authors of the 
present study aimed to review the up-to-date guidelines 
and recommendations and to analyze the management 
protocols for OAB patients, including cases with urgency 
urinary incontinence.
The present recommendations are supposed to serve as 
a guide to therapeutic management both, for gynecologists 
and other specialists. Considering the continuous advances 
in the field of pathophysiology and pharmacotherapy, the 
strategies presented herein will need to be updated in due 
course. 
Overactive bladder is a symptom complex associated 
with the phase of urine storage. The International Conti-
nence Society defines OAB as a urinary urgency, typically 
with frequency and nocturia, with or without urinary incon-
tinence. The diagnosis can be made after ruling out urinary 
tract infections, post-void urine retention, or changes such 
as cancer, urinary calculi or pelvic tumors modeling the 
bladder [1]. Pelvic organ prolapse (POP) may be the cause 
of OAB symptoms in the affected women. In the experience 
of the authors, the diagnosis of OAB should be made after 
excluding POP as the cause of OAB symptoms. On the other 
hand, numerous specialists believe that symptomatic POP 
should not influence the diagnosis and treatment of OAB.
A detailed diagnostic process is necessary to confirm 
the diagnosis of OAB before treatment. Also, other disor-
ders, which might constitute the underlying causes for the 
reported symptoms, should be excluded. The following 
methods may be used in the diagnostic process: medical 
history, physical examination, urinalysis, urine culture, urine 
cytology, evaluation of post-void urinary retention, micturi-
tion diary, ultrasound examination, cystoscopy, urodynamic 
examination, and validated questionnaires to diagnose UI 
types, OAB severity, and health-related quality of life [2–4]. 
Importantly, a urodynamic examination is not necessary 
during the initial assessment and is not the essential condi-
tion to initiate treatment. The diagnostic process and test 
selection are tailored to the individual needs and symptoms 
of the patient. Guidelines for the diagnostic process of pa-
tients with OAB will have been presented elsewhere.
Objectives
The aim of the Urogynecology Section of the Polish 
Society of Gynecologists and Obstetricians (PSGO) was to 
develop interdisciplinary recommendations for the manage-
ment of overactive bladder (OAB) syndrome, based on the 
available literature reports, expert knowledge, and everyday 
practice. The up-to-date standards, indications and expert 
opinions on the clinical management of OAB are presented.
MATERIAL AND METHODS
In 2005, 2006 and 2010, the panel of PSGO experts devel-
oped guidelines for the diagnosis and treatment of urogy-
necologic conditions. The present publication is an update 
of those recommendations, based on the literature reports 
published between 2010 and 2019, as well as the recom-
mendations of the American Urological Association, the 
European Association of Urology, and the Canadian Urologi-
cal Association [2–7].
The literature, including the current international rec-
ommendations for the management of overactive bladder, 
urinary incontinence, urgency urinary incontinence and 
mixed urinary incontinence, was reviewed.
Special attention has been paid to the level of evidence 
and degree of recommendation of the available data sourc-
es. If the literature source seemed insufficient, expert opin-
ions and management protocols were included. 
RECOMMENDATIONS
First-line treatment: behavioral therapy with 
pelvic floor muscle training
According to the recommendations of the Ameri-
can Urological Association (AUA) [2], education of the 
patient (resulting in active involvement in the therapy), 
lifestyle modifications, and various types of behavioral 
therapy combined with pelvic floor muscle training (PFMT), 
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should constitute the first-line treatment for the OAB syn-
drome. It is important to establish if the cognitive abilities 
of the patient will allow for an effective implementation of 
the management. From the very beginning of the therapy, 
the first line of treatment may be combined with pharma-
cotherapy, i.e., the second line. In everyday practice, both 
lines of treatment are often used simultaneously from 
the start. Patient motivation is of utmost importance as 
it determines lifestyle changes and strict adherence to 
treatment regime, which directly affects the efficacy of 
the treatment (Fig. 1). 
Behavioral therapy includes:
a) actions aimed at improving bladder function, i.e., 
scheduled voiding at time intervals and bladder train-
ing, allowing for gradual increase of the time intervals 
between voids 
b) control of fluid intake and reduction of caffeine intake
c) lifestyle modifications, including weight control, ces-
sation of smoking, and bowel regularity to prevent 
constipation.
Pelvic floor muscle training is an example of physical 
therapy used to treat OAB. In certain cases, it is also advisable 
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• Consider dose adjustment or
switching to another drug if the
therapy proves to be eective but
side eects require treatment
discontinuation
 
• Consider combination therapy
(antimuscarinics with β3-
adrenoceptor agonist) in patients
resistant to monotherapy
Re-evaluation of the symptoms;
consider urine culture,
evaluation of post-void urinary
retention, micturition diary,
symptom questionnaires 
In patients with moderate- and high-
intensity symptoms consider:
1. Botulinum toxin
 • (patient must accept the risk of the self-
catheterization)
or
2. Posterior Tibial Nerve Stimulation
(PTNS)
 • (patient must accept the need for
frequent follow-up appointments)
or
3. Sacral Nerve Stimulation (SNS)
Figure 1. Management of patients with non-neurogenic overactive bladder syndrome [by M.E. Grzybowska, on the basis of Gormley EA, Lightner 
DJ, Burgio KL, et al. Diagnosis and Treatment of Non-Neurogenic Overactive Bladder (OAB) in Adults: an AUA/SUFU Guideline (2019). Published 
2012; Amended 2014, 2019. https://www.auanet.org/guidelines/overactive-bladder-(oab)-guideline (access: 2020.01.10)] 
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The choice of treatment depends on the symptoms and 
patient preferences. Most patients do not experience com-
plete symptom resolution after the first line of treatment.   
Second-line treatment: oral and vaginal 
pharmacotherapy
In everyday clinical practice, pharmacotherapy is typi-
cally initiated together with the first-line treatment as it is 
already applicable in the initial stages of OAB therapy.
After reviewing the available recommendations for OAB 
treatment, it seems prudent to follow the guidelines is-
sued by the American Urological Association [2], with minor 
modifications.
1. Oral antimuscarinics or β3-adrenoceptor agonists are 
used as the second-line treatment.
2. If both, immediate release (IR) and extended release (ER) 
drugs are available, ER drugs are preferred due to lower 
risk for dry mouth.
3. In the event of insufficient symptom control and/or 
serious side effects after administering an antimus-
carinic drug, the dose may be modified or another an-
timuscarinic drug or a β3- adrenoceptor agonist may 
be initiated. 
4. A combination therapy (antimuscarinics combined with 
β3-adrenoceptor agonists) may be considered for pa-
tients who failed on antimuscarinic or β3-adrenoceptor 
agonist monotherapy.
5. Antimuscarinics are contraindicated in patients with 
narrow-angle glaucoma. Patients with glaucoma should 
be referred to an ophthalmologist for a consultation 
before anticholinergic drugs are considered. 
6. Antimuscarinics should be used with caution in patients 
with impaired gastric emptying or history of urinary 
retention.
7. Adequate fluid intake, bowel management, dose modifica-
tion or switching to another antimuscarinic or mirabegron 
should be recommended to patients with constipation 
who are satisfied with the effects of the OAB treatment 
with antimuscarinics before treatment discontinuation.
8. Adequate fluid intake, hydration of the oral cavity, dose ad-
justment or switching to another antimuscarinic or mirabe-
gron should be recommended to patients with dry mouth 
who are satisfied with the effects of the OAB treatment 
with antimuscarinics before treatment discontinuation.
9. Before antimuscarinic therapy is initiated, patient use 
of other drugs with anticholinergic properties should 
be taken into consideration.
10. Mirabegron is effective and safe in older popula-
tions. Caution is advised when prescribing antimus-
carinic drugs to frail patients.
11. Vaginal estrogen therapy may effectively alleviate OAB 
symptoms in postmenopausal women. It is recom-
mended to combine β3-adrenoceptor agonists or an-
timuscarinics with estrogens in that group of patients.
12. The efficacy of pharmacotherapy may be assessed after 
4–8 weeks. Then, the effects of the treatment should 
be evaluated, and the necessary adjustments 
should be introduced, if needed. 
13. Patients with behavioral and pharmacologic therapy re-
sistant OAB should be referred to a specialist for further 
diagnostic procedures and therapeutic options.
Third-line treatment: botulinum toxin and 
neuromodulation (posterior tibial nerve 
stimulation and sacral nerve stimulation)
Botulinum toxin
1. Patients with first- and second-line therapy resistant 
OAB may be offered bladder wall injection of botulinum 
toxin A.  
2. Patients should be informed about the limited dura-
tion of drug action and the risk for both, urinary tract 
infections and the need for self-catheterization (it is 
important to ensure the patient will cooperate and be 
willing to perform it, if necessary). The patient is required 
to report for post-void residual volume evaluation after 
the procedure.
3. The next bladder wall injection of botulinum toxin 
should be performed no sooner than three months 
after the pervious injection.
Posterior tibial nerve stimulation (PTNS)
In some patients, posterior tibial nerve stimulation 
(PTNS) may be used as third-line treatment. Transcutane-
ous PTNS is performed by a physiotherapist using adhesive 
surface electrodes.  Percutaneous needle PTNS, performed 
by a physician, consists in stimulation with a slim needle 
electrode. In both cases, the electrodes are placed just above 
the medial condyle of the ankle.
Sacral nerve stimulation (SNS)
Sacral nerve stimulation (SNS) may be offered as 
third-line treatment to carefully selected patient popula-
tions with severe therapy resistant OAB symptoms or those 
who are not eligible for second-line treatment but are willing 
to undergo surgery.
Fourth-line treatment 
Augmentation cystoplasty or other types of urine diver-
sion may be considered in rare and complicated cases of 
therapy resistant OAB [2].
Patient care
Care and monitoring should be exercised during therapy 
to assess patient adherence to their treatment recommen-
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dations and efficacy of the therapy, or to consider other 
therapeutic options.
Additional therapeutic procedures
Indwelling catheters (transurethral, suprapubic, etc.) are 
not recommended in the management of OAB due to the 
unfavorable risk-to-benefit ratio, with some exceptions [2].
As for manual therapy, the following techniques may 
be used: myofascial relaxation of the pelvic floor mus-
cles and the lumbar-pelvic-iliac complex, joint mobiliza-
tion/manipulation of the spine and the pelvis, and nerve 
neuromobilization. Manual therapy allows the normali-
zation of pelvic floor and anterolateral abdominal wall 
muscle tone, which affects nerve conduction within the 
pelvis. The literature offers limited amount of data on the 
matter. Based on the expert knowledge and experience of 
the authors of the present study, manual therapy is a useful 
tool in OAB therapy.
OVERVIEW OF THE RECOMMENDATIONS
First-line treatment: behavioral therapy 
combined with pelvic floor muscle training
Actions improving the urinary bladder function
Timed voiding (at fixed intervals) — initiated by the 
affected patients or their caretakers — improves urinary 
continence, especially in older people with cognitive impair-
ment (LE1b — level of evidence) [3].
Bladder training, typically combined with pelvic floor 
muscle training, is one of the basic elements of behavioral 
therapy. It gradually extends the time intervals between 
voiding, increases the bladder volume and reduces the 
number of urgency urinary incontinence (UUI) episodes 
(LE1b). The goal of the bladder training is for the patient 
to adhere to a voiding schedule, with gradually delayed 
voiding (by 15–30 minutes/week) until the goal of a 2–3- 
-hour interval is achieved. Bladder training is used to correct 
urination habits. Combined with an anticholinergic and/or 
β3-agonist therapy, bladder training may be a more effec-
tive way of dealing with the symptoms of frequency and 
nocturia than any of these therapies alone (LE1b) [3].
According to a Cochrane analysis of 23 studies and 
3685 patients, symptom resolution was more frequently 
observed in patients receiving antimuscarinics as compared 
to bladder training alone (RR 0.74, 95% CI 0.61–0.91), and 
in patients receiving antimuscarinics in combination with 
bladder training than bladder training alone (RR 0.57, 95% 
CI 0.38–0.88) [8].
Fluid intake management
Caffeine is found in beverages such as coffee, tea and 
cola. Reduced caffeine intake may diminish the symptoms 
of urgency and frequency (LE2b) [3]. 
Modification of fluid intake, depending on the ini-
tial balance of fluid intake and output, has been advised. 
In a randomized controlled trial (RCT), limitation of the fluid 
intake by 25% reduced the symptoms of urgency, frequency 
and nocturia in patients with OAB [3].
Caution should be exercised when recommending fluid 
restriction, as this strategy is often self-initiated by the af-
fected patients to reduce the symptoms, before seeking 
medical help. Minimum daily fluid intake should be ap-
proximately 1500 mL or 30 mL/kg of body weight. In order 
to reduce the symptoms of nocturia, patients can be advised 
to limit their fluid intake after 6 p.m. (or 3–4 hours before 
bedtime) and to redirect fluid intake to the morning and 
afternoon hours [4, 9].
Lifestyle modification
In RCT, an 8% weight reduction in obese women result-
ed in a 42% reduction in the episodes of UUI as compared to 
26% in the control group [2, 10]. The literature offers reports 
which confirm that the increase in the body mass index 
(BMI) corresponds to the increase in the incidence of UUI. 
Obesity (BMI > 30 kg/m2) is believed to be an independent 
risk factor for OAB [3, 11, 12].
Smoking cessation seems to be weakly correlated with 
symptom alleviation in patients with urinary frequency [3, 11]. 
Nicotine, being an irritant, is considered a risk factor for OAB 
symptoms in both, former and current smokers (LE3) [13].
The literature offers a considerable number of reports on 
higher prevalence of chronic constipation in patients with 
OAB [4, 14]. Charach et al., demonstrated that the treatment 
of constipation reduces the symptoms of urgency and fre-
quency in older patients (LE4) [4, 15]. However, according to 
the recommendations of the European Association of Urology 
(EAU), no evidence supports the alleviation of OAB symptoms 
after reduction of constipation [3]. High-fiber diet is standard 
medical approach to the management of constipation [3, 4]. 
Pelvic floor muscle training
Pelvic floor muscle training combined with urgency sup-
pression techniques is often based on biofeedback (real-time 
ultrasonography feedback, EMG-biofeedback) with elec-
trostimulation. The patients learn how to respond to urgency, 
which in turn reduces its intensity and delays the need to 
void. Six to ten quick pelvic contractions may be performed. 
If done correctly, and in the absence of parasympathetic 
and sympathetic dysfunction, they allow the detrusor to be 
temporarily relaxed. The contractions must be performed at 
optimal times to ensure optimal benefit (LE3) [4, 16].
Summary
Although most patients do not experience complete 
symptom resolution after behavioral therapy, significant 
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Table 1. Recommendation grade for behavioral therapy [31]
Therapeutic method Grade
Lifestyle modifications (BMI reduction, smoking cessation, 
adequate diet, fluid management, bowel management) A–C
Bladder training, scheduled voiding B
BMI — body mass index
Table 2. Recommendation grade for physiotherapy [31]
Physiotherapeutic method Grade
Pelvic floor muscle training A
Pelvic floor muscle training with biofeedback B
Electrostimulation B
Posterior tibial nerve stimulation (PTNS) A
reduction in symptom intensity and improved quality of 
patient life have been reported. The absence of side effects 
which might accompany the pharmacotherapy in the next 
stages of treatment is an important benefit. Eight to twelve 
weeks is the optimal duration of behavioral therapy, after 
that time the effects of the treatment should be evaluated 
and modified, if necessary [2].
Promotion of healthy habits associated with the func-
tioning of the lower urinary tract, including the blad-
der, should become an element of routine medical care. 
Lifestyle modifications and other behavioral techniques 
should always be discussed with the patient, not only to 
optimize treatment results but also to educate the patient. 
The grades of recommendations for behavioral and physi-
otherapy are presented in Tables 1 and 2.
Second-line treatment: pharmacological therapy
1. Oral medications
Pharmacotherapy of OAB aims to reduce urgency, fre-
quency, and urgency urinary incontinence, thus improving 
the quality of patient life. Increased ‘warning time’, i.e., time 
from the onset of the urgency to void or incontinence, is one 
of the most important outcomes of the drug therapy. Cur-
rently, antimuscarinic drugs and β3-adrenoceptor agonist 
(mirabegron) are the most used medications in OAB therapy. 
Combination pharmacotherapy which uses drugs with dif-
ferent mechanisms of action alleviates OAB symptoms more 
effectively as compared to monotherapy, with a comparable 
rate of side effects, and is recommended in patients with 
insufficient clinical response. An ideal medication should 
be safe, effective, well-tolerated, and the patients should 
comply with the treatment regime for the required amount 
of time.
The following antimuscarinic drugs are available for 
OAB treatment: trospium, oxybutynin, tolterodine — im-
mediate release (IR) and extended release (ER), fesoterodine, 
darifenacin, and solifenacin. Their mechanisms of action and 
half-life are presented in Table 3. All the above- mentioned 
medications have a high grade (Grade A) of recommenda-
tion, though some of them are not currently available in Po-
land. The effects of various antimuscarinics were compared 
in a systematic review and the conclusions are presented 
below. The efficacy and side effects of the therapy were 
evaluated. The daily number of micturitions, urgency and 
leakage episodes were analyzed, as well as patient-reported 
subjective assessment of the treatment efficacy. Most of 
the available studies analyzed the treatment efficacy after 
a relatively short period of time — 12 weeks.
Conclusions from the Cochrane review [17]
Out of immediate release drugs, tolterodine is preferred 
over oxybutynin — despite similar efficacy rates — due 
to the lower risk for side effects, especially dry mouth. 
The recommended dose is 2 mg twice daily, but 1 mg may 
be equally effective, with a lower risk for side effects. Extend-
ed-release medications are preferred due to significantly 
reduced risk for mucosal dryness. Tolterodine ER should be 
the drug of choice compared to oxybutynin and tolterodine 
IR (LE1a). Fesoterodine demonstrated better effectiveness 
as compared to tolterodine ER but was associated with 
higher therapy discontinuation rates due to its adverse 
effects and (mainly) dry mouth. The recommended dose 
of solifenacin is 5 mg daily and may be increased to 10 mg 
daily, with elevated risk for dry mouth. Solifenacin was more 
effective and had lower rates of dry mouth as compared to 
tolterodine IR (LE1a). Solifenacin (10 mg) and tolterodine 
(8 mg) were more effective than their doses of 5 mg and 




Oxybutynin has a mixed action. It blocks the calcium 
channel, and has an anticholinergic as well as a local anes-
thetic effect, although the latter is relevant only in case of 
intravesical instillation therapy. Oxybutynin is a non-selec-
tive antagonist of the muscarinic (M) receptors, with higher 
affinity for M1 and M3 receptor subtypes than M2. M3 re-
ceptors are in the salivary glands, which is the reason for 
high incidence of dry mouth reported by patients using 
immediate-release oxybutynin [18]. Only a small number of 
patients continue the treatment for longer than six months 
due to the side effects (dry mucous membranes, constipa-
tion, blurred vision, somnolence, etc.) [18, 19].
Oral drugs with extended release and the transder-
mal patches and gels are available, but not in Poland. 
The transdermal route allows to lower the total dose and 
242
Ginekologia Polska 2021, vol. 92, no. 3
www. journals.viamedica.pl/ginekologia_polska
leads to fewer dose-related side effects, increasing therapy 
continuation rates.
The drug penetrates the blood-brain barrier and may 
cause cognitive disorders so it should not be used in older 
patients (LE2b) [3].
Trospium chloride
Trospium chloride has an anticholinergic non-selective 
effect on the muscarinic receptors. It does not penetrate 
the blood-brain barrier, so it does not negatively affect the 
cognitive functions of the patient. Trospium chloride has 
a documented effect in the reduction of smooth muscle 
tension, among others in the urogenital and gastrointestinal 
tract, allowing for the relaxation of the detrusor muscle and 
reduction of the uncontrolled detrusor contractions [20]. 
Trospium efficacy has been demonstrated, both compared 
to the placebo and other anticholinergics. After 12 weeks 
of therapy (20 mg twice daily) with trospium, mean voided 
volume increased by 36 mL, whereas mean number of mic-
turitions decreased by three per day and urgency leakage 
episodes by two per day [20, 21]. In a long-term (52 weeks) 
study, the efficacy of trospium was like oxybutynin, but with 
better overall tolerance [22].
Tolterodine
The parent drug, tolterodine, and its active metabolite, 
5-hydroxymethyl tolterodine (5-HMT), are responsible for 
the effect. Tolterodine has low lipophilicity, which is the 
reason for its very limited penetration into the central nerv-
ous system and no adverse effects on the cognitive func-
tions. It exhibits non-selective activity against the M receptor 
subtypes and has a higher affinity for the bladder than for 
the salivary glands [19]. The use of tolterodine resulted in 
a significantly reduced number of micturitions and urgency 
incontinence episodes (LE1a) in various randomized tri-
als. After 12 weeks of therapy, symptom reduction was as 
follows: UUI — 80%, urgency — 78%, nocturnal frequency 
— 40%, and daytime frequency — 30% [23].
Fesoterodine
Fesoterodine, a non-selective anticholinergic, is a pro-
drug which is hydrolyzed to 5-hydroxymethyl tolterodine 
Table 3. Overactive bladder syndrome — drug characterization
International name Half-life Mechanism of action Dosing Grade of  recommendation
Antimuscarinic drugs
Trospium 18.3 h Non-selective anticholinergic action 2 × 20 mg/day A
Oxybutynin 2 h
Non-selective anticholinergic 
action (higher affinity for M1 and 
M3 than M2)
blocks the calcium channel 
Local anesthetic effect
3 x 5 mg A
Tolterodine 
2–3 h
5-HMT (Tolterodine metabolite) 
3–4 h
Non-selective anticholinergic action
2 × 1–2 mg
Extended release:




Metabolized in the serum to 
5-HMT
7–9 h
Non-selective anticholinergic action 1 × 4–8 mg A
Darifenacin 12 h M3 7.5 or 15 mg/day A
Solifenacin 45–68 h M2, M3 1 × 5–10 mg A
β3-adrenoceptor agonist
Mirabegron 50 h β3-adrenoceptor agonist 50 mg/day A
Other
Estrogens C
Botulinum toxin 100 u.200 u. A
Resiniferatoxin, Capsaicin Intravesical C
Antidiuretic  Desmopressin Indicated in nocturnal polyuria A
α-adrenergic receptor blocker – C
5-HMT — 5-hydroxymethyl tolterodine metabolite
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after oral administration. Fesoterodine is a specific, but 
non-selective, oral antimuscarinic which acts as a competi-
tive antagonist of muscarinic receptors. 5-HMT is an active 
metabolite, same as the metabolite formed from tolterodine. 
Part of 5-HMT is metabolized in the liver, but > 15% of the 
administered dose is eliminated unchanged with the urine. 
The dose-dependent clinical effect of fesoterodine has been 
confirmed but it was associated with increased adverse 
effects [24]. After 12 weeks of therapy with fesoterodine, 
mean daily number of micturitions decreased by 2.2, ur-
gency episodes by 3.5, and urgency urinary incontinence 
episodes by almost 2, whereas mean voided volume in-
creased by 33 mL. No statistically significant reduction in the 
number of nocturia episodes was observed. In comparison 
to tolterodine ER, fesoterodine was statistically significantly 
more effective in reducing the number of urgency incon-
tinence episodes and increasing the voided volume [25]. 
Fesoterodine does not prolong the QT/QTc interval, either 
at therapeutic or higher doses [19].
Darifenacin
Darifenacin has an 11-fold higher affinity for M3 than for 
M2 receptor subtypes. Its inhibitory activity of bladder con-
traction is comparable to that of atropine, at the same time 
demonstrating a 5-fold lower affinity for the muscarinic 
receptors in the salivary glands. Darifenacin was developed 
as a controlled-release preparation to address the incon-
venience of multiple dosing per day. It is metabolized in 
the liver by the P450 cytochrome, is moderately lipophilic, 
and has no negative impact on the cognitive functions. Dar-
ifenacin is an M3-selective receptor antagonist, however, 
its role in developing constipation symptoms has been 
increasingly reported. After a two-year follow-up, 20.9% of 
the patients reported constipation as compared to 7.9% 
in the placebo group, and 5.6% were required to use fiber 
supplements, stool softeners or laxatives [26]. Darifenacin 
does not prolong the QT/QTc interval [18]. Significant im-
provement in OAB symptom intensity was observed already 
after 6–8 days of therapy [27]. After 12 weeks of therapy 
with the dose of 7.5 mg and 15 mg, mean daily number of 
micturitions decreased by 1.6 and 1.7, urgency episodes 
by 2, and urgency incontinence episodes by 4.0 and 4.7, 
respectively. Darifenacin did not significantly impact the 
number of nocturia episodes [28].
Solifenacin
Solifenacin is a competitive inhibitor of the muscarinic 
M3 receptor and has low affinity for other M receptors 
(M2 and M1). Solifenacin has higher affinity for the urinary 
bladder than for the salivary glands. It has a long half-life, 
and its slow pharmacokinetics is associated with steady ef-
ficacy and reduced side effects. Solifenacin is metabolized 
in the liver via the cytochrome P450 system. First significant 
therapeutic effects may be observed as early as on day 7 of 
therapy, with the maximum effect after 28 days. Randomized 
controlled trials demonstrated the efficacy of solifenacin 
to be higher as compared to placebo or tolterodine. In the 
STAR study, after 12 weeks of therapy with 5 mg of solif-
enacin/day, mean daily number of micturitions decreased 
by 2.5, urgency episodes by 3.1, and urgency incontinence 
episodes by 1.5. Solifenacin at the dose of 5 mg was more 
effective in reducing the number of urgency and urgency 
incontinence episodes and was associated with lower pad 
use as compared to 4 mg of tolterodine ER. At the endpoint 
of the study, 59% of solifenacin and 49% of tolterodine ER 
users did not experience UUI episodes, and the difference 
was statistically significant [24, 29].
In the group of patients with multiple sclerosis and after 
spinal injuries, 10 mg of solifenacin improved the urody-
namic parameters, including an increase in the maximum 
cystometric capacity of the bladder (by 134 mL) as compared 
to the placebo group (by 5 mL) [30].
Mirabegron
Mirabegron is a β3-adrenoceptor agonist. The sympa-
thetic nervous system regulates the urine storage phase, and 
the β-adrenergic receptors present in the bladder mediate 
the relaxation of the detrusor and foster urine accumula-
tion. There are three β receptor subtypes: β1, β2, β3. Ap-
proximately 97% of the β-adrenergic receptors in the urinary 
bladder are β3 receptors [31]. Stimulation of β3-adrenergic 
receptors increases bladder capacity without changing the 
micturition pressure or residual volume. In consequence, 
β3-adrenoceptor agonist increases bladder capacity with-
out affecting the contraction amplitude during micturition 
[32]. The recommended daily dose is 50 mg, with 25 mg for 
patients with severe renal impairment (creatinine clearance 
15–29 mL/min) or moderate liver impairment.
Four large, randomized trials demonstrated mirabegron 
efficacy in reducing OAB symptoms as compared to placebo. 
In a study by Khullar et al. [33], after 12 weeks of therapy with 
50 mg of mirabegron, mean daily number of micturitions 
decreased by 1.9, episodes of urinary incontinence by 1.6, 
and of urgency by 2.3, while mean voided volume increased 
by 24 mL. The incidence of treatment-related adverse events 
(hypertension, urinary tract infection, headache, naso-
pharyngitis) was similar in the mirabegron and the placebo 
groups. Additional analysis revealed a similar efficacy of 
mirabegron as far as the number of incontinence episodes 
and micturitions was concerned, both in OAB patients with 
no history of antimuscarinic therapy (treatment naïve) and 
those who had discontinued prior antimuscarinic therapy 
[34]. The SYNERGY I and II studies confirmed higher efficacy 
of the combination therapy (solifenacin and mirabegron) as 
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compared to the monotherapy. The combination therapy 
additionally decreased mean daily number of micturitions 
by 0.1–0.5 and of incontinence episodes by 0.4–0.5, and 
increased mean voided volume by another 13–16 mL per 
micturition [35].
Antidepressants
Imipramine is an antidepressant used in the treatment 
of OAB but is currently unavailable in Poland [36]. It ex-
erts a complex pharmacological impact through its anti-
muscarinic activity as well as serotonin and noradrenaline 
reuptake blocking properties. Imipramine has an indirect 
α-adrenergic effect, thus promoting detrusor relaxation 
and causing an increase in the intraurethral pressure [37].
Duloxetine is a norepinephrine and serotonin reuptake 
inhibitor, and weakly inhibits dopamine reuptake. Dulox-
etine increases the activity of the urethral sphincters in the 
urine storage phase [19]. The Onuf nucleus is a distinct group 
of motor neurons, located in anterior horns of the spinal 
cord in the sacral segment, and is the origin of the pudendal 
nerve. Through the pudendal nerve, the Onuf nucleus in-
nervates the urethral striated muscles. Noradrenaline and 
serotonin potentiate the glutaminergic stimulation of the 
motor neurons, increasing striated muscle contraction [19].
Most research so far has focused on the use of dulox-
etine to treat stress urinary incontinence, but few reports 
concerned its beneficial effect in OAB therapy. Duloxetine 
reduces the daily number of micturitions and urgency 
episodes and improves the quality of patient life, while 
mean voided volume remains unchanged (LE4). The effi-
cacy of duloxetine therapy has been confirmed in patients 
with detrusor overactivity and mixed urinary incontinence. 
In light of its efficacy in treating depression, duloxetine may 
present a therapeutic option for patients with depression 
and concomitant OAB symptoms (off-label use, the drug 
is not registered for urinary incontinence in Poland) [36].
Management of nocturia with concurrent overactive bladder
Desmopressin (DDAVP, deamino-D-arginine vasopres-
sin) is a synthetic analogue of vasopressin and exhibits 
antidiuretic activity through vasopressin V2 receptors, af-
fecting water reabsorption in the renal tubules. Desmo-
pressin is used in the treatment of nocturia caused by noc-
turnal polyuria [3]. The recommended daily dose is 25 µg 
for women (50 µg for men) of desmopressin lyophilizate, 
administered sublingually, one hour before bedtime. Food 
may reduce drug strength and effect duration. Some studies 
support the efficacy of desmopressin for treating nocturia 
in patients with OAB. A randomized trial compared the use 
of combination therapy (25 µg of desmopressin and 4 mg 
of tolterodine ER) versus tolterodine monotherapy. After 
12 weeks of therapy, a significant difference in the nocturnal 
urine volume and prolonged time between the initial sleep 
point and the first episode of nocturia were observed in 
the desmopressin group of patients treated for OAB and 
nocturnal polyuria.
Administration of desmopressin may be considered in 
patients affected by nocturia with concurrent OAB to reduce 
the number and volume of nocturnal micturitions [38].
Therapy continuation
Numerous studies demonstrated low continuation rates 
of antimuscarinic therapy, mainly due to patient-reported 
lack of results and adverse effects. Wagg et al. [39], re-
ported the following results for therapy continuation after 
12 months: 35% — solifenacin, 28% — tolterodine ER, 26% 
— trospium, 24% — tolterodine IR, 22% — oxybutynin IR, 
and 17% — darifenacin [39]. However, after 24 months, the 
rates of therapy continuation ranged from 6 to 12% [40]. 
According to the literature, mirabegron has a significantly 
longer time to therapy discontinuation as compared to 
antimuscarinics. After 12 months of therapy, 38% of the 
patients continued mirabegron. Mean time to mirabegron 
and tolterodine ER discontinuation was 169 and 56 days, 
respectively. Factors promoting therapy discontinuation in 
OAB patients included: younger age (< 60 years), insufficient 
information about the purpose of treatment, exceedingly 
high expectations about the therapy effects, reluctance to 
use chronic pharmacotherapy, or significant alleviation of 
OAB symptoms [19].
Cardiovascular effects
Drug selection for OAB therapy needs to include the pos-
sible effect of chronic pharmacotherapy on the cardiovascular 
system [41]. The safety profile of antimuscarinics has been 
confirmed by numerous studies. Unfortunately, the risk for 
developing drug-induced cardiac events and symptoms such 
as increased heart rate (HR), prolonged QT interval, and poly-
morphic ventricular tachycardia is a cause for some concern 
[42]. The M2 receptors are predominant muscarinic receptor 
subtypes expressed in the heart and they play an important 
role in the maintenance of the heart rate and cardiac output. 
M2 receptor blockade in the sinus node, the heart’s natural 
pacemaker, increases the pulse and decreases other param-
eters of the vagal tone, e.g., return to resting heart rate after 
exertion and baroreceptor reflex response [42].
Darifenacin selectivity for M3 receptors is suggestive of 
a minor effect on the cardiovascular system. Olshansky et 
al., evaluated the effects of a seven-day treatment regimen 
with 15 mg/day of darifenacin, 4 mg/day of tolterodine and 
placebo in healthy participants. Tolterodine was found to sig-
nificantly increase the heart rate as compared to darifenacin 
and placebo, while darifenacin did not affect the heart rate as 
compared to placebo. The maximum increase in HR for tolter-
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odine occurred at times of maximum plasma concentration 
and was approximately 4 bpm [43]. Fesoterodine was also 
found to cause a dose-related increase in HR. Mean change in 
HR for 4 and 8 mg of fesoterodine and placebo was 3, 4 and 
1 bpm, respectively [44]. As for oxybutynin, no increase in 
HR as compared to placebo was observed [45]. 
Solifenacin did not cause an increase in mean HR or 
mean blood pressure [46]. Trospium therapy may be associ-
ated with dose-related increase in HR. Mean increase in HR 
after trospium was 9 bpm for the 20 mg dose and 18 bpm 
for the 100 mg dose. The increase in HR was noted after 
4-8 hours and disappeared 12 hours after administration. 
No significant effect on the blood pressure was detected, re-
gardless of the dose [19]. In conclusion, darifenacin, solifena-
cin, and oxybutynin show no significant effect on HR [47].
In a study with placebo, mirabegron increased HR by 
1–2 bpm [48]. A pooled analysis of clinical trial data found 
no proof of increased risk for cardiovascular adverse events 
for mirabegron or antimuscarinic therapy as compared to 
placebo. Cardiovascular adverse events were related to 
the pre-existing conditions of the patients, not the OAB 
pharmacotherapy. No correlation between OAB treat-
ment and increased risk for adverse cardiac events was 
demonstrated [49]. In the SYNERGY study, which analyzed 
combination therapy with mirabegron and solifenacin, no 
statistically significant increase in resting blood pressure 
was observed [50]. The analysis of the safety profile for 
the combination therapy with mirabegron and solifenacin 
revealed comparable rates of adverse cardiovascular events 
for both, combination and monotherapy [50].
QT-interval prolongation and its consequences result 
from inhibition of the cardiac hERG potassium channel [42]. 
Among antimuscarinics, darifenacin, fesoterodine and tro-
spium chloride do not affect the QT/QTc interval [19, 42, 
51]. Solifenacin may prolong the QT interval but not to 
a clinically relevant degree (10 mg — by 2 milliseconds, 
30 mg — three times the maximum therapeutic dose — by 
8 milliseconds) [19]. The effect of tolterodine on the QT in-
terval correlates with its plasma concentration. Tolterodine 
blocks hERG channels with high affinity but produces little 
QT prolongation clinically [42]. Data on the possible QT ef-
fects in patients using oxybutynin are limited [19, 42, 52]. 
Studies on mirabegron monotherapy found no effect on the 
QT/QTc interval, either in the study group or in the combina-
tion therapy with solifenacin or placebo [50]. Imipramine has 
a negative effect on the cardiovascular system; it prolongs 
the QTc interval and has a potent antiarrhythmic action [19].
Polypharmacy and metabolism
Polypharmacy (> 5 drugs) is a common phenomenon in 
the older populations. Drug interactions frequently involve the 
P450 cytochrome hepatic isoenzymes. Tolterodine, darifena-
cin, solifenacin, oxybutynin, and mirabegron are metabolized 
by the P450 cytochrome system. Consequently, susceptibil-
ity to altered drug metabolism in case of drug interactions 
of medications based on hepatic metabolism is increased. 
Trospium is eliminated unchanged through the kidneys [19].
Anticholinergic burden
Anticholinergic burden should be considered when 
treating patients who use polypharmacy. Numerous drugs 
from other groups have an additional anticholinergic activity 
(antimuscarinics together with antidepressants and antihis-
tamines constitute > 90% of medications with anticholin-
ergic properties prescribed to patients). The additive effect 
of the drugs can be expressed as higher number of adverse 
effects (dry mouth, constipation, blurred vision, cognitive 
impairment) and lower effectiveness. The anticholinergic 
effect of the drugs is dose-dependent [53]. Various scales 
are used to assess the overall anticholinergic effect of the 
drugs [54]. The list of selected drugs with high and low an-
ticholinergic potential is presented in Table 4 [55]. 
Pharmacotherapy in older patients
Mirabegron is effective and safe in older populations 
(LE1b). Antimuscarinics are equally effective in older patients 
and other age groups (LE1b). Over time, the impact of an-
ticholinergic drugs on the cognitive functions increases with 
drug accumulation (LE2b). Oxybutynin may worsen cogni-
tive functions in older patients, so it is not recommended 
for people over the age of 65 years (LE2b). In short-term 
studies, solifenacin, darifenacin, fesoterodine, and trospium 
were not found to cause cognitive dysfunction in older 
patients. Long-term antimuscarinic therapy should be used 
with caution in older patients, especially those at risk for 
developing cognitive impairment [2, 3].
2. Vaginal estrogens
The role of estrogens in OAB therapy remains ambiguous 
and they are not included in most international guidelines. Pa-
tients with estrogen deficiency have been confirmed to be at 
an increased risk for OAB [56]. In rat models after ovariectomy, 
a significant reduction in voided volume and an increase in 
micturition frequency were observed, and the administration 
of exogenous estrogen reversed these changes [57].
A systematic review of 11 randomized trials demonstrat-
ed the efficacy of estrogens versus placebo in reducing the 
number of frequency, nocturia, urgency, and incontinence 
episodes, and increasing bladder volume and bladder volume 
at the first sensation. These results pertained to local therapy 
(vaginal and intravesical). Systemic therapy was effective 
only in reducing the number of incontinence episodes and 
increasing the bladder volume at the first sensation, while at 
the same time intensifying the symptoms of nocturia [58].
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The results of studies which compared the use of anti-
muscarinic drugs in combination with intravaginal estro-
gen versus antimuscarinic monotherapy remain conflict-
ing. Tseng et al., demonstrated significant improvement in 
frequency, voided volume, and quality of life among women 
who received tolterodine and vaginal conjugated equine es-
trogen treatment as compared to tolterodine monotherapy. 
Symptoms of nocturia, urgency and UUI after treatment 
improved as compared to baseline, but the combination 
therapy was not superior [59]. Serati et al. [60], analyzed 
a group of women with detrusor overactivity confirmed 
by urodynamic tests and showed no synergistic effect of 
4 mg of tolterodine ER and estriol cream in OAB therapy. 
Jiang et al., showed that solifenacin efficacy in reducing 
OAB symptoms was identical in combination with vaginal 
estradiol and without estrogens. However, the addition of 
estradiol significantly improved patient-reported subjective 
impressions and quality of life [61].
THIRD-LINE TREATMENT: BOTULINUM TOXIN 
AND NEUROMODULATION (POSTERIOR 
TIBIAL NERVE STIMULATION AND SACRAL 
NERVE STIMULATION)
Botulinum toxin
1. Patients with OAB resistant to first- and second-line 
therapy may be offered onabotulinumtoxin A (100 U) 
bladder wall injections [3].
2. Patients should be informed about the limited duration 
of action of the drug, the risk of urinary tract infection 
and the possibility of self-catheterization (make sure the 
patient will be cooperative). The patient is required to 
return for post-void residual evaluation [3].
3. The next injection should not be performed within three 
months. In clinical trials, the median duration of the ef-
fect was 166 days (approx. 24 weeks) [3, 62].
Onabotulinumtoxin A belongs to the A group of toxins. 
It is a neurotoxin which binds permanently to the neuromus-
cular junction, paralyzes neuromuscular conduction by frag-
menting the synaptosomal-associated protein 25 (SNAP-25) 
and inhibiting the release of acetylcholine from the presyn-
aptic terminal.
Onabotulinumtoxin A is used in idiopathic detrusor 
overactivity (IDO) at the dose of 100 U dissolved in 10 mL of 
saline and injected into 20 points of the bladder wall above 
the bladder trigone (0.5 mL per injection site). Different 
types of type A botulinum toxin are currently available on 
the market, including those not registered for OAB treat-
ment (abobotulinumtoxin A and incobotulinumtoxin A). 
Considerable attention should be paid to the registered 
indications of the drugs, especially in the absence of dose 
equivalence for these preparations [3].
In a randomized trial after 12 weeks of follow-up, on-
abotulinum significantly reduced all OAB symptoms as com-
pared to the placebo group, decreased the daily number 
of UUI episodes (–2.95 vs –1.03; p < 0.001), and positively 
affected the quality of patient life (positive response to treat-
ment was reported by 62.8% of the patients as compared 
to 26.8% in the placebo group) [63]. UUI episodes were not 
Table 4. Anticholinergic drugs and their anticholinergic potential 
[54, 55]





























Drugs which affect the musculoskeletal system (M)
Baclofen 1
Tizanidine 2




Drugs which affect the cardiovascular system (C)
Digoxin 1
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reported by 22.9% of the patients in the onabotulinum 
group and 6.5% in the placebo group [62].
In a study comparing onabotulinum with antimus-
carinics after 6 months of follow-up, both methods proved 
to be associated with a similar reduction in the frequency 
of UUI episodes (3.3 vs 3.4, respectively). However, com-
plete resolution of UUI symptoms occurred in 27% of 
the patients in the onabotulinum group and only 13% in 
the antimuscarinic group (p = 0.003). The onabotulinum 
group had significantly lower probability of dry mouth 
(31% vs 46%, respectively), but higher probability of urine 
retention (5% vs 0%, respectively in the first 2 months 
of therapy) and urinary tract infections (33% vs 13%, re-
spectively). The treatment effect was maintained in 38% 
of the patients after 12 months of onabotulinum therapy 
(LE1b) [3, 64].
In case of neurogenic detrusor overactivity (NDO), the 
recommended dose of onabotulinum is 200 U (30 intra-det-
rusor muscle injections at the dose of 1 mL per site), in which 
case median duration of the drug effect is 256–295 days 
according to phase III studies [65].
Other bladder injection protocols
The concept of preventing vesicoureteral reflux is the 
main reason behind injecting the area above the trigone. 
However, several studies investigated other locations for 
bladder onabotulinum injections [19].
The studies which compared various sites of bladder in-
jections did not demonstrate any increase either in post-void 
urine retention, or the rates of patients requiring self-cath-
eterization, or the vesicoureteral reflux in cases when the 
injections were performed into the trigone [19]. In one study 
among patients with idiopathic detrusor overactivity (IDO), 
three types of injection sites were compared: body of the 
bladder (100U); body of the bladder (75U) and the trigone 
(25U); as well as the fundus (50U) and the trigone (50U). 
The success rate at three months of follow-up was 70% for 
the body of the bladder, 74% for the body and trigone, and 
73% for the fundus and trigone. No statistically significant 
differences were found in success rates, number of urgency 
and UUI episodes, or long-term measures among the three 
subgroups. The incidence of adverse events was similar in 
the three groups. No vesicoureteral reflux was detected in 
any of the patients [66].
In contrast, a meta-analysis of eight studies and 419 pa-
tients with NDO and IDO revealed that trigone injections 
were more effective and were not associated with higher 
complication rate as compared to trigone-sparing injec-
tions. Injection depth did not affect the efficacy or safety 
of onabotulinumtoxin A [67]. 
The most common side effects of onabotulinumtoxin 
are related to the urinary tract. At 12 weeks of follow-up, 
uncomplicated UTI were found in 15.5% of the patients 
in the onabotulinumtoxin group and in 5.9% in the pla-
cebo group. Additionally, symptoms of dysuria (12.2%), 
bacteriuria (5%) and urinary retention (5.4%) were reported. 
An increase in post-void residual (PVR) of ≥ 200 mL as com-
pared to baseline was observed in 8.7% of the patients. No sig-
nificant increase in PVR was observed in the placebo group. 
The rate of patients who required self-catheterization at any 
time during the first treatment cycle was 6.1% as compared 
to 0% in the placebo group [68]. 
Posterior tibial nerve stimulation (PTNS)
Percutaneous tibial nerve stimulation (PTNS) may be 
used as third-line treatment in some patients [3]. 
The tibial nerve is a peripheral nerve, with sensory and 
motor fibers. It originates from the L4–S3 spinal nerve roots, 
which are also responsible for the sensory and motor inner-
vation of the urinary bladder and the pelvic floor. The PTNS 
effect is believed to be related to the retrograde stimulation 
of the sacral nerve plexus. The treatment typically consists 
in 12 weekly sessions, 30 min each, after which mainte-
nance therapy sessions are recommended. The stimula-
tion is performed percutaneously using a slim 34-Gauge 
needle inserted just above the medial condyle of the ankle 
(P-PTNS) [3].
PTNS is effective in treating therapy resistant OAB. 
It demonstrates significantly higher efficacy as compared 
to placebo, without serious side effects, and comparable 
efficacy to antimuscarinic therapy (LE1b). According to 
various meta-analyses, PTNS shows 37–100% effectiveness 
and decreases the number of frequency, urgency, UUI and 
nocturia episodes [69]. Stimulation with transcutaneous 
electrodes (T-PTNS), whose effectiveness in reducing day-
time frequency is comparable to P-PTNS, is also an available 
treatment modality (LE1b) [70].
P-PTNS maintenance therapy, performed approximately 
once a month, proved to be effective in maintaining the 
treatment effect for up to three years of follow-up (LE1b) 
[3]. It can also be conducted with adhesive skin surface elec-
trodes (T-PTNS) in a weekly three-session regimen (30 min/ 
/session), (LE1b) [71].
In OAB patients, a physiotherapist may use vaginal, tran-
srectal and transcutaneous electrostimulation (paraspinal 
electrostimulation of the micturition centers, non-invasive 
electrostimulation of the tibial or peroneal nerves). Based 
on the available sources, it is challenging to determine the 
sufficient number of sessions. Also, there is no consensus 
on the duration of one series of the electrostimulation. The 
authors of the present study recommend that the elec-
trostimulation parameters be adjusted individually, taking 
into consideration the condition of the patient and symp-
tom severity [72, 73].
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Sacral nerve stimulation (SNS)
SNS may be suggested as the third-line treatment 
to carefully selected populations of patients with severe 
therapy resistant OAB or those not eligible for second-line 
treatment and willing to undergo surgery [2]. In Poland, 
only a handful of procedures have been performed so far 
so the experience is limited. The efficacy of SNS is higher 
if juxtaposed with the option of continuing unsuccessful 
conservative treatment to treat UUI (LE1b) [3].
The efficacy of SNS was demonstrated in patients with 
therapy resistant UUI. At six months of follow-up, 50% of the pa-
tients after SNS implantation showed over 90% improvement 
as far as UUI symptoms were concerned as compared to 1.6% 
in the group with continuous pharmacotherapy (LE1b) [74].
In a prospective randomized study in patients resis-
tant to therapy with at least one antimuscarinic drug, at six 
months of follow-up 86% of the patients in the SNS group 
reported improved or very much improved OAB symptoms 
as compared to 44% in the antimuscarinic group (p < 0.001). 
The therapeutic success rate for SNS was 85% at 12 months 
and 82% at five years of follow-up. Therapeutic success was 
defined as at least 50% improvement in UUI episodes or 
at least 50% improvement in the daily number of micturi-
tions, or a return to the normal daily number of micturitions 
(< 8 per day). At five years of follow-up, mean daily number 
of UI episodes decreased by 2.0 ± 2.2 as compared to base-
line (p < 0.0001), and complete continence was achieved 
in 45% of the patients. Mean daily reduction in the number 
of micturitions was 5.4 ± 4.3 (p < 0.0001). At 12 months of 
follow-up, the most common device-related adverse events 
included ‘undesirable’ change in stimulation in 12%, im-
plant site pain in 7%, and implant site infection in 3% of 
the patients. The cumulative five-year rate of lead-related 
adverse events which required reoperation after complete 
implantation was 22.4%. Ineffectiveness of the therapeutic 
product was observed in 13% of the patients. At five years 
of follow-up, the rate of patients with device removal was 
19.1% (LE1b) [75].
In a ROSETTA study, which compared SNS with injec-
tions of 200 U of onabotulinum at six months of follow-up, 
patients in the onabotulinum group had higher reduction in 
the mean daily number of UUI episodes as compared to the 
SNS group (–3.9 vs –3.3 episodes/day; p = 0.01). They also re-
ported significantly greater improvement in the Overactive 
Bladder Questionnaire SF, which evaluates symptom bother, 
and a higher level of satisfaction with the treatment. Urinary 
tract infections were significantly more frequent in patients 
from the onabotulinum group (35% vs 11%, p < 0.001) as 
well as the need for self-catheterization (8% at 1 month, 4% 
at 3 months, and 2% at 6 months of follow-up). The need for 
device revisions and removals was found in 3% of the pa-
tients. The small but significant difference in subjective and 
objective indices of therapy efficacy reported in that study 
gave rise to a heated debate about the clinical significance 
of the obtained results [76]. Based on that, the consensus in 
the European recommendations is that SNS efficacy is not 
superior to injection therapy with 200 units of onabotulinum 
at six months of follow-up (LE1b) [3].
Although SNS constitutes the third-line treatment, 
along with PTNS and onabotulinum, it should be treated 
as a higher-risk and more invasive method. Therefore, it is 
recommended to patients who are resistant to other meth-
ods of treatment [4].
In addition to OAB therapy, SNS is also effective in treat-
ing painful bladder syndrome, interstitial cystitis, urine re-
tention not induced by bladder outlet obstruction, and fecal 
incontinence [69].
SNS and magnetic resonance imaging
SNS is a relative contraindication for magnetic resonance 
imaging (MRI). The magnetic field generates electric currents 
in the neuroelectrodes, which heats the electrodes in vivo 
and in vitro, and may cause nerve damage. Device removal 
is recommended if elective MRI is required. In newer devices, 
it is possible to perform a head examination under highly 
specified conditions [69].
SUMMARy
Before treatment commencement, it is necessary to con-
duct an adequate and thorough diagnostic process. If the 
therapy proves ineffective, the patient needs to be referred 
to a specialist. In selected situations, a multidisciplinary team 
consultation may be recommended. 
Pharmacotherapy remains the gold standard in OAB 
treatment and should not be delayed. However, the limita-
tions and side effects of pharmacotherapy are the reasons 
why the search for new solutions continues. Animal studies 
are conducted to find new drugs to treat the OAB syndrome 
[19, 36, 77–80]. Preclinical studies lead to the development 
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możliwości terapeutyczne. Przegląd Urologiczny. 2010; 6(64): 10–13.
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